EndoChoice Holdings Inc (GI) was Resumed by JP Morgan to “Overweight”. JP Morgan advised their investors in a research report released on Jul 13, 2016.
On the company’s financial health, EndoChoice Holdings Inc reported $-0.68 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on May 4, 2016. Analyst had a consensus of $-0.54. The company had revenue of $18.46 million for the quarter, compared to analysts expectations of $18.34 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.00 EPS.
EndoChoice Holdings Inc closed down -0.1 points or -1.98% at $4.94 with 78,870 shares getting traded on Monday. Post opening the session at $5.01, the shares hit an intraday low of $4.89 and an intraday high of $5.05 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 16, 2016, Mark Gilreath (CEO) purchased 20,000 shares at $5.06 per share price. According to the SEC, on Mar 14, 2016, David L Kaufman (director) purchased 89,450 shares at $4.81 per share price. On Mar 11, 2016, J Scott Carter (director) purchased 49,995 shares at $4.66 per share price, according to the Form-4 filing with the securities and exchange commission.
ECPM Holdings LLC is a medical device company. The Company is focused on designing and commercializing a platform of products for gastrointestinal (GI) caregivers. It offers a range of products and services that span single-use devices and infection control products pathology and imaging systems. The Company’s Fuse system an endoscopy system used for visualization of the GI tract and related therapeutic interventions enables a wider field of view for upper and lower endoscopy procedures. The Fuse colonoscope offers a 330? view of the colon during colonoscopy instead of the 140? to 170? view offered by standard colonoscopes. Its CinchPad is used to improve the transport process of endoscopes after use. The Company’s products are used in colonoscopy and esophagogastroduodenoscopy (EGD) and other procedures of the upper GI tract. The Company serves over 2500 GI departments that perform endoscopic procedures.